Literature DB >> 33574335

Promoting versatile vaccine development for emerging pandemics.

Joshua T Monrad1,2,3, Jonas B Sandbrink4,5, Neil G Cherian6,7.   

Abstract

The ongoing COVID-19 pandemic has demonstrated the importance of rapid and versatile development of emergency medical countermeasures such as vaccines. We discuss the role of platform vaccines and prototype pathogen research in modern vaccine development, and outline how previous pathogen-specific funding approaches can be improved to adequately promote vaccine R&D for emerging pandemics. We present a more comprehensive approach to financing vaccine R&D, which maximises biomedical pandemic preparedness by promoting flexible vaccine platforms and translatable research into prototype pathogens. As the numerous platform-based SARS-CoV-2 vaccines show, funders can accelerate pandemic vaccine development by proactively investing in versatile platform technologies. For certain emerging infectious diseases, where vaccine research can translate to other related pathogens with pandemic potential, investment decisions should reflect the full social value of increasing overall preparedness, rather than just the value of bringing a vaccine to market for individual pathogens.

Entities:  

Year:  2021        PMID: 33574335     DOI: 10.1038/s41541-021-00290-y

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  6 in total

1.  Brief exposure of skin to near-infrared laser augments early vaccine responses.

Authors:  Shinya Yokomizo; Wataru Katagiri; Yohei Maki; Tomoya Sano; Kazumasa Inoue; Masahiro Fukushi; Dmitriy N Atochin; Toshihiro Kushibiki; Akihiko Kawana; Yoshifumi Kimizuka; Satoshi Kashiwagi
Journal:  Nanophotonics       Date:  2021-08-09       Impact factor: 7.923

2.  The rapid progress in COVID vaccine development and implementation.

Authors:  Alan D T Barrett; Richard W Titball; Paul A MacAry; Richard E Rupp; Veronika von Messling; David H Walker; Nicolas V J Fanget
Journal:  NPJ Vaccines       Date:  2022-02-10       Impact factor: 7.344

3.  Pandemic-response adenoviral vector and RNA vaccine manufacturing.

Authors:  Zoltán Kis; Kyungjae Tak; Dauda Ibrahim; Maria M Papathanasiou; Benoît Chachuat; Nilay Shah; Cleo Kontoravdi
Journal:  NPJ Vaccines       Date:  2022-03-02       Impact factor: 7.344

Review 4.  COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Authors:  Kuldeep Dhama; Manish Dhawan; Ruchi Tiwari; Talha Bin Emran; Saikat Mitra; Ali A Rabaan; Saad Alhumaid; Zainab Al Alawi; Abbas Al Mutair
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

5.  Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.

Authors:  M Cristina Cassetti; Theodore C Pierson; L Jean Patterson; Karin Bok; Amanda J DeRocco; Anne M Deschamps; Barney S Graham; Emily J Erbelding; Anthony S Fauci
Journal:  J Infect Dis       Date:  2022-07-25       Impact factor: 7.759

Review 6.  Recombinant vaccines in 2022: a perspective from the cell factory.

Authors:  Marianna Teixeira de Pinho Favaro; Jan Atienza-Garriga; Carlos Martínez-Torró; Eloi Parladé; Esther Vázquez; José Luis Corchero; Neus Ferrer-Miralles; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2022-10-05       Impact factor: 6.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.